Delving into the Latest Updates on AureoGen, Inc. with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

重组多肽	1

排名前五的靶点	数量

IPC synthase(肌醇磷脂酰神经酰胺合成酶)	1

关联

2

项与 AureoGen, Inc. 相关的药物

Aureobasidin A-based cyclic peptides(AureoGen, Inc.)

靶点

IPC synthase

作用机制

IPC synthase抑制剂

在研机构

Merck Sharp & Dohme Corp. [+1]

原研机构

AureoGen, Inc.

在研适应症

真菌病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

EPP (AureoGen Biosciences)

靶点-

作用机制-

在研机构-

原研机构

AureoGen, Inc.

在研适应症-

非在研适应症

细菌感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 AureoGen, Inc. 相关的临床结果

登录后查看更多信息

0 项与 AureoGen, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 AureoGen, Inc. 相关的文献（医药）

A novel approach to generating broad-spectrum antifungal drug candidates from the natural product compound aureobasidin A

作者: Metzger, Brian ; Elhammer, Ake ; Simons, Lloyd J. ; Wuts, Peter G. ; Slightom, Jerry ; Sterling, Rachel

There is currently an immediate unmet need for new and better drugs to treat of systemic fungal infections.The natural product aureobasidin A (AbA) is a well-tolerated antifungal agent with robust efficacy in animals and a mode of action that is distinct from all drugs in current clin. use.However, although native AbA is active, and quite potent, against essentially all yeasts, as well a number of other fungi, it has little activity against the filamentous fungus Aspergillus fumigatus.A.fumigatus is an important human pathogen and attempts to improve AbA′s activity this organism, by structural modifications, have to date involved chemistries too complex and costly for continued development.AureoGen has developed an entirely new, and much simpler, approach to modify the structure of AbA.The key step in the chem. involves functionalization of the phenylalanine residues in the compound by iridium-catalyzed borylation.This is followed by displacement of the pinacol boron moiety to form the corresponding bromide or iodide and substitution by Suzuki biaryl coupling.The chem. allows for synthesis of a truly wide range of derivatives and has to date produced compounds with A.fumigatus minimal inhibitory concentrations of < 0.12 μg/mL.The approach is also readily adaptable to large-scale synthesis and industrial production

100 项与 AureoGen, Inc. 相关的药物交易

登录后查看更多信息

100 项与 AureoGen, Inc. 相关的转化医学

登录后查看更多信息